Investment Thesis
iBio is a pre-commercial pharmaceutical company with minimal revenue ($100K) and massive operating losses (-$23.8M), burning -$17M annually with no clear path to near-term profitability. While the balance sheet is strong with $47.6M cash and zero debt, fundamentals indicate the company has ~2.8 years of cash runway at current burn rates but lacks sufficient revenue generation to justify ongoing operational scale.
Strengths
- Strong cash position of $47.6M providing ~2.8 years of operational runway
- Excellent liquidity with 11.88x current ratio and zero debt leverage (0x debt/equity)
- Revenue growth of 77.8% YoY shows early commercialization momentum, though from minimal base
Risks
- Operating cash burn of -$17.0M annually with free cash flow deeply negative, unsustainable at current burn rate
- Negligible revenue of $100K insufficient to cover operating expenses of -$23.8M, indicating pre-commercial stage with years to profitability
- Pharmaceutical sector execution risk: high R&D costs, regulatory approval uncertainty, and clinical trial failures without visible pipeline progress in fundamentals
- Questionable data quality: Gross Profit ($2.2M) exceeds Revenue ($100K), suggesting potential accounting or data reporting issues
Key Metrics to Watch
- Absolute revenue growth trajectory and path to positive operating cash flow
- Cash burn rate and months of runway remaining
- Clinical trial progress and regulatory milestones for pipeline products
Financial Metrics
Revenue
100.0K
Net Income
-22.4M
EPS (Diluted)
$-0.25
Free Cash Flow
-17.5M
Total Assets
85.8M
Cash
47.6M
Profitability Ratios
Gross Margin
2,167.0%
Operating Margin
-23,761.0%
Net Margin
-22,443.0%
ROE
-28.9%
ROA
-26.1%
FCF Margin
-17,549.0%
Balance Sheet & Liquidity
Current Ratio
11.88x
Quick Ratio
11.88x
Debt/Equity
0.00x
Debt/Assets
9.7%
Interest Coverage
-212.15x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-13T06:39:14.700133 |
Data as of: 2026-03-31 |
Powered by Claude AI